Maria Teresa L. S.
- Country
- Italy
- Department
- UO Ematologia e Trapianto Midollo Osseo- Disease unti Trapianto allogenico e Terapie Cellulari
Research Overview
- Efficacy of MC0518 Allogeneic Mesenchymal Stromal Cells in Adult Patients with Grade II–IV Acute Graft-Versus-Host Disease Refractory to Corticosteroids and Ruxolitinib
- Evaluation of Belumosudil and Prednisone Versus Placebo and Prednisone in Patients Aged 12 and Older with Newly Diagnosed Chronic Graft-Versus-Host Disease
- Evaluation of Itolizumab and Corticosteroids for Initial Management of Acute Graft Versus Host Disease in a Phase 3 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 91 of 144 partner sites.
Specializations
Transplant Complications
This investigator specializes in treating complications following bone marrow transplantation, with particular emphasis on both acute and chronic forms of graft-versus-host disease (GVHD).
- Acute GVHD Management
- Chronic GVHD Treatment
- Post-transplant Care
The investigator explores innovative therapeutic approaches in combination with traditional corticosteroid treatments.
Immunotherapy Research
The investigator focuses on novel immunomodulatory agents including belumosudil, itolizumab, and axatilimab for treating transplant-related complications.
- Novel Drug Development
- Combination Therapy Approaches
- Treatment Response Assessment
Their work involves evaluating new therapeutic combinations to improve patient outcomes in transplant medicine.
Clinical Outcomes
The investigator studies event-free survival and early disease response in patients with transplant-related complications.
- Treatment Efficacy Assessment
- Disease Response Monitoring
- Long-term Outcome Analysis
Their research evaluates therapeutic interventions for moderate to severe manifestations of post-transplant complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.